Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. (Q46563541)
Jump to navigation
Jump to search
scientific article published in October 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. |
scientific article published in October 2013 |
Statements
1 reference
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. (English)
1 reference
Manuela Ceccarelli
1 reference
Chiara Lobetti-Bodoni
1 reference
Barbara Mantoan
1 reference
Carola Boccomini
1 reference
Elisa Genuardi
1 reference
Giuseppe Rossi
1 reference
Alessandro Pulsoni
1 reference
Luigi Rigacci
1 reference
Antonello Pinto
1 reference
Sara Galimberti
1 reference
Delia Rota-Scalabrini
1 reference
Angela Ferrari
1 reference
Francesco Zaja
1 reference
Andrea Gallamini
1 reference
Enrica Gamba
1 reference
Andrea Evangelista
1 reference
Fondazione Italiana Linfomi
1 reference
1 October 2013
1 reference
1 reference
122
1 reference
3759-3766
1 reference
23
1 reference
Identifiers
1 reference
1 reference